Logotype for DocGo Inc

DocGo (DCGO) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for DocGo Inc

Q2 2026 earnings summary

10 Sep, 2026

Executive summary

  • Announced the largest acquisition to date: Hicuity Health, a leading acute and critical care telemedicine provider, with $65M in trailing 12-month revenue and $4.5M in adjusted EBITDA; entered definitive agreement to acquire Hicuity Health, expanding virtual care capabilities and cross-selling opportunities.

  • Secured a new funding commitment from Perceptive Advisors, including a $50M term loan and assumption of $52M in Hicuity debt, maturing in December 2029.

  • Achieved record volumes across key business lines, including double-digit growth in U.S. medical transportation, healthcare in the home, and virtual care.

  • Net loss for Q2 2026 was $18.0M, up from $13.3M in Q2 2025, driven by the wind-down of large migrant-related contracts and lower Mobile Health Services revenue.

  • Advanced integration of technology and care delivery, aiming to create a holistic, tech-powered healthcare platform spanning hospital to home.

Financial highlights

  • Q2 2026 revenue was $73.4M, down from $80.4M in Q2 2025 due to the wind-down of migrant-related projects; excluding these, revenue grew 19% year-over-year.

  • Medical transportation revenue rose to $52M from $49.6M year-over-year, setting a new quarterly record.

  • Mobile health revenue was $21.4M, down from $30.8M, but non-migrant mobile health revenue surged 78% year-over-year.

  • Adjusted EBITDA loss improved sequentially to $6.3M from $10.3M last quarter, but was slightly higher than the $6.1M loss in Q2 2025; adjusted EBITDA margin for Q2 2026 was (8.6)%.

  • Cash and equivalents at June 30, 2026: $48.1M; available cash $25.2M.

Outlook and guidance

  • Full-year 2026 revenue guidance narrowed to $305M–$310M, representing 21%–23% growth over 2025 base revenues, excluding Hicuity.

  • Full-year adjusted EBITDA loss expected at $17M–$22M, wider than previous guidance due to slower-than-expected cost reductions.

  • Company expects to achieve a positive adjusted EBITDA run rate exiting 2026, setting up for a strong 2027.

  • Management expects Mobile Health Services revenue to remain lower in 2026 due to the absence of migrant-related projects, despite growth in other business lines.

  • Cost containment and cash preservation remain priorities, with plans to reduce cash utilization and operating costs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more